YUNNAN BAIYAO GROUP CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.72 CNY | +2.22% |
|
-4.72% | +11.33% |
| May. 13 | Yunnan Baiyao's Unit to Conduct Clinical Trials on Prostate Cancer Drug | MT |
| May. 13 | Yunnan Baiyao to Conduct Clinical Trials on Flurbiprofen Gel Patch | MT |
ETFs positioned on Yunnan Baiyao Group Co.,Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.68% | 2 M€ | -12.41% | - | |
| 1.32% | 2 M€ | -14.14% | ||
| 1.18% | 4 M€ | -2.96% | ||
| 0.13% | 35 M€ | -5.85% | - | |
| 0.11% | 3 M€ | +7.82% | - | |
| 0.10% | 4 M€ | -11.56% | ||
| 0.05% | 11 M€ | +5.79% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.01% | 2,867 M€ | +9.57% | - | |
| 0.01% | 153 M€ | +6.72% | - | |
| 0.01% | 454 M€ | +8.54% | - | |
| 0.01% | 112 M€ | +4.06% | - | |
| 0.00% | 32 M€ | +7.48% | - | |
| 0.00% | 7 M€ | +5.02% | - | |
| 0.00% | 34 M€ | +3.39% | - | |
| 0.00% | 34 M€ | +8.24% | - | |
| 0.00% | 391 M€ | +8.67% | - | |
| 0.00% | 39 M€ | +5.65% | - | |
| 0.00% | 306 M€ | +5.68% | - |
Yunnan Baiyao Group Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical products. The group proposes primarily traditional medicine products, phytobiological products, body care products, antibiotics and anti-inflammatory.
China accounts for 98.9% of net sales.
Sector
Pharmaceuticals
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
54.72
CNY
Average target price
64.08
CNY
Spread / Average Target
+17.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.33% | 13.22B | |
| +29.98% | 684B | |
| +30.34% | 568B | |
| -3.52% | 361B | |
| +18.59% | 329B | |
| +4.07% | 284B | |
| +16.21% | 240B | |
| +9.66% | 208B | |
| -6.83% | 200B | |
| +7.09% | 166B |
- Stock Market
- Equities
- 000538 Stock
- Funds and ETFs Yunnan Baiyao Group Co.,Ltd